The University of North Carolina at Chapel Hill

University of Florida Research Foundation Inc

Joseph E Rabinowitz

Richard Jude Samulski

Mavis Agbandje-McKenna

Weidong Xiao

Chengwen Li

Paul E Monahan

Dawn E Bowles

Josh Grieger

The present invention is based, in part, on the discovery that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. The inventors have discovered that in some cases as little as a single amino acid insertion or substitution from a first parvovirus (e.g., an AAV) into the capsid structure of another parvovirus (e.g., an AAV) to create a chimeric parvovirus is sufficient to confer one or more of the desirable properties of the first parvovirus to the resulting chimeric parvovirus and/or to confer a property that is not exhibited by the first parvovirus or is present to a lesser extent.

Chimeric vectors

The invention uses recombinant parvoviruses, and particularly recombinant adeno-associated virus (rAAV) to deliver genes and DNA sequences for gene therapy following manipulation of the therapeutic virus for packaging and transport. The invention delivers therapeutic viral vectors via rAAV affixed to support matrixes (i.e., sutures, surgically implantable materials, grafts, and the like).

Methods and compounds for controlled release of recombinant parvovirus vectors

The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors.

Virus vectors and methods of making and administering the same

Recombinant parvovirus vectors and method of making

Growing community of inventors

Carrboro, NC, United States of America

Joseph E Rabinowitz